SLC6A3 and Parkinson disease: For instance, in Parkinson’s disease, dopamine transporter imaging techniques such as DaT 123I–FP-CIT scans and alpha-synuclein-specific PET (once available) can provide insights into the disease’s pathology, while fALFF and ALFF may serve as non-invasive, in vivo indicators of functional alterations (Lin et al. 2022, Khan et al. 2023, Sanchez-Rodriguez et al. 2024a).